According to related industries, Amgen's bone formation promotion and bone resorption inhibitor Evenity (Romosozumab) has so far been prescribed in Big 5 general hospitals such as SMC, SNUH, Seoul St. hospital, AMC, and Shinchon Severance Hospital, and has passed the drug commitee (DC) of about 30 medical institutions such as Gangnam Severance Hospital, Pusan National University Hospital, Bundang Seoul National University Hospital, and Hanyang University Hospital.

Amgen submitted an application for registration about one year after Evenity's domestic approval in May 2019, and was recognized for the adequacy of benefits from the HIRA's Pharmaceutical Benefit Advisory Committee in September.